Sanofi (SNY)
| Market Cap | 95.16B -24.2% |
| Revenue (ttm) | 55.89B +7.0% |
| Net Income | 4.52B -56.6% |
| EPS | 1.86 -55.6% |
| Shares Out | 1.20B |
| PE Ratio | 21.04 |
| Forward PE | 8.05 |
| Dividend | $1.76 (4.39%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 2,902,925 |
| Open | 40.18 |
| Previous Close | 40.20 |
| Day's Range | 39.58 - 40.27 |
| 52-Week Range | 39.18 - 52.68 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 53.61 (+33.26%) |
| Earnings Date | Oct 30, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 nov... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $53.61, which is an increase of 33.26% from the latest price.
News
Regeneron (REGN) Reports Q3 R&D Charge Amid $8B Immunology Deal Expansion with Sanofi
Regeneron (REGN) Reports Q3 R&D Charge Amid $8B Immunology Deal Expansion with Sanofi
Sanofi: Availability of the aide-mémoire for Q3 2026 results
Availability of the aide-mémoire for Q3 2026 results Paris, France - October 6, 2026. Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sano...
Press Release : Availability of the aide-mémoire for Q3 2026 results
Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026. Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi....
As First Dupixent MDL Hearing Opens, Weitz & Luxenberg Points to Sanofi's Own Words on a Cancer That Hides Behind Eczema
NEW YORK--(BUSINESS WIRE)--Weitz & Luxenberg, which represents more people in the Dupixent litigation than any other firm, appeared this past Friday at the first hearing in the federal multidistrict l...
Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®
The six-time NBA All-Star, three-time All-NBA selection, 2016 NBA Rookie of the Year, and 2026 NBA Champion Karl-Anthony Towns brings his personal experience with COVID-19 to encourage eligible people...
Sanofi SA and Regeneron Investor Event Transcript
Sanofi SA and Regeneron Investor Event Transcript
Regeneron price target raised to $930 from $870 at Jefferies
Jefferies raised the firm’s price target on Regeneron (REGN) to $930 from $870 and keeps a Buy rating on the shares. The company’s expanded collaboration with Sanofi (SNY) on four…
Expanded Sanofi agreement particularly favorable for Regeneron, says TD Cowen
TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $960 price target on Regeneron (REGN), saying the expanded agreement with Sanofi (SNY) enhances both companies’ ability to capitalize…
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
Regeneron Pharmaceuticals NASDAQ: REGN and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, addi...
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
Regeneron and Sanofi NASDAQ: SNY announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the block...
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%Regeneron and Sanofi (NASDAQ:SNY) announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory ...
Sanofi Transcript: Collaboration
The expanded partnership will jointly develop and commercialize next-generation long-acting antibodies for Type 2 inflammatory diseases, sharing costs and profits equally. The alliance leverages both companies' R&D and commercial strengths to address unmet needs and sustain market leadership.
Sanofi Press release: Collaboration
Sanofi issued a press release on October 1, 2026, disclosing material business information to investors.
Sanofi Slides: Collaboration
Sanofi has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
Regeneron, Sanofi expand long-standing antibody collaboration
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced an expansion of their long-standing antibody collaboration, adding multiple next-generation, long-acting antibodies to the alliance that has...
Sanofi Expands Collaboration with Regeneron in Immunology with $10 Billion Upfront Payment
Sanofi Expands Collaboration with Regeneron in Immunology with $10 Billion Upfront Payment
Sanofi, Regeneron Expand Immunology Alliance In Deal Worth Up To $8 Bln
(RTTNews) - Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) on Thursday announced an expanded global collaboration to develop and commercialise four next-generation, long-acting immunology antibodie...
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.
Sanofi & Regeneron Expand Alliance With Four Next-Gen Antibodies
(RTTNews) - On Thursday, Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) announced the expansion of their global collaboration to develop and commercialize four next-generation, long-acting immunolo...
Sanofi: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed...
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
French drugmaker Sanofi said on Thursday it would pay US partner Regeneron $1 billion upfront and up to $7 billion more in milestone payments to add four next-generation, long-acting immunology an...
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed b...
Sanofi (SAN) -- Navigating Challenges and Opportunities | Oldfield Partners - Overstone Global ...
Sanofi (SAN) -- Navigating Challenges and Opportunities | Oldfield Partners - Overstone Global Equity Fund 2026 Q2
Sanofi (EPA:SAN) -- Navigating Challenges and Opportunities | Oldfield Partners - Overstone ...
Sanofi (EPA:SAN) -- Navigating Challenges and Opportunities | Oldfield Partners - Overstone Global All Cap Value Fund 2026 Q2